2024-518216-39-00尚未招募2 期
Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Safety Profile: relevant adverse events (AE), serious AEs (SAE), withdrawal due to AEs/SAE
研究概览
简要总结
Safety profile of COMBI therapy in patients with polycythemia Vera after 24 months
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •The participant must meet criteria 1–3 AND at least one of 4–8
- •Age ≥ 18 years AND
- •A confirmed diagnosis of PV according to the WHO 2016 criteria AND
- •A negative test for active or latent tuberculosis (from within the last month)
- •Biochemical evidence of active disease as defined by a) Elevated hematocrit and/or red cell count and/or b) Leucocyte count > 10 x 109/L and/or c) Platelet count > 400 x 109/L. OR
- •Hypermetabolic symptoms such as weight loss (> 10% within 6 months), night sweats and subfebrilia (temperature> 38 º C for more than 2 weeks without signs of infection OR
- •Pruritus OR
- •Symptomatic splenomegaly OR
- •Presence of previous thrombosis
排除标准
- •Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug. Participants must use contraceptives during the entire study period*.
- •Other active malignancy within the past 5 years (not including non-melanoma skin cancer and prostate cancer without need for treatment).
- •ECOG function scores> / = 3
- •Serum creatinine more than 2 x ULN
- •Total serum bilirubin greater than 1.5 x ULN
- •Plasma ALAT more than 3 x ULN
- •Former psychiatric disorder (depression diagnosed by a psychiatrist)
- •Uncontrolled metabolic (endocrinological) disease.
- •Severe heart disease (heart failure NYHA class 3-4).
- •Severe myelosuppression. (WBC<1.5 Mill/L, PLA<100)
- •Chronic hepatitis with decompensated cirrhosis.
- •Chronic hepatitis in patients who have been or recently (within 6 months) has been treated with immunosuppressive drugs except for corticosteroid treatment.
- •Epilepsy and / or other serious CNS disorders. *Spiral, birth control pills, implants, transdermal patch, vaginal ring or transdermal injection. Sterile / infertile subjects are exempt from the use of contraception. To be considered sterile or infertile, one must generally be surgically sterilized (vasectomy, bilateral tubectomy, hysterectomy or ovariectomy) or be postmenopausal, defined as absent menstruation for at least 12 months before study enrollment.
结局指标
主要结局
Safety Profile: relevant adverse events (AE), serious AEs (SAE), withdrawal due to AEs/SAE
Safety Profile: relevant adverse events (AE), serious AEs (SAE), withdrawal due to AEs/SAE
次要结局
- 1. Safety Profile: adverse events (AE), serious AEs (SAE), withdrawal, AEs/SAEs 2. Efficacy Profile: a) Proportion of patients achieving complete hematological remission (HCT < 45, PLA ≤400 and WBC < 10) after 3, 6, 8, 9, 12, 18 and 24 months. b) Remission rates at 12 and 24 months. c) JAK2V617F allele burden measured at baseline and after 3,6,12 and 24 months. d) Proportion of patients suffering thrombosis and/or hemorrhage at 12 at 24 months. with more e)-j)
研究者
Sponsor/PI Hans Hasselbalch
Scientific
Region Sjaelland
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Combination therapy of interferon-alpha and interleukin-2 for patients with metastatic renal cell carcinoma after failure of targeted therapy because of adverse eventsJPRN-UMIN000017717Department of Urology, The University of Tokyo Hospital30
已完成
不适用
Efficacy of combination therapy IFN-alpha-2b and ribavirin for patients with Serogroup2 and high titer HCV / without Serogroup1 and high titer HCV.Hepatitis CJPRN-C000000196Osaka university graduate school of medicine200
进行中（未招募）
不适用
Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis - NDChonic hepatitis HCV-relatedMedDRA version: 9.1Level: SOCClassification code 10019805MedDRA version: 9.1Level: SOCClassification code 10038359EUCTR2010-023245-30-ITISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI
进行中（未招募）
不适用
COMBINED THERAPY WITH PEG-INTERFERON-a, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA - NDpatients anti-HCV, HCV RNA positivity, Na?ve, with cryoglobulinemic vasculitis (detection of serum cryoglobulins associated with purpura, arthralgias and weakness)and with chronic hepatitisMedDRA version: 9.1Level: SOCClassification code 10005329EUCTR2010-020659-30-ITAZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
进行中（未招募）
1 期
Kombinationsbehandling med Interferon og JAK1-2 Hæmmer i behandlingen af Ph-Negativ Myeloprolifertiv CancerEUCTR2013-003295-12-DKRoskilde University Hospital50